|  |
| --- |
| December 4, 2013 |
|  |
| Contact person economic press Dr. Edda Schulze  Corporate Press  Phone +49 201 177-2225  Fax +49 201 177-3030  edda.schulze@evonik.com |
| Contact person specialized press  Stefan Cornelissen  Corporate Innovation Strategy & Management  Phone +49 201 177-4327  Fax +49 201 177-4322  stefan.cornelissen@evonik.com |
| Evonik Industries AG  Rellinghauser Straße 1-11  45128 Essen Germany  Phone +49 201 177-01  Telefax +49 201 177-3475  www.evonik.de  **Supervisory Board**  Dr. Werner Müller, Chairman  Executive Board  Dr. Klaus Engel, Chairman  Dr. Thomas Haeberle,  Thomas Wessel, Patrik Wohlhauser, Ute Wolf, Dr. Dahai Yu  Registered office Essen  Registered court  Essen local court  Commercial registry B 19474  VAT ID no. DE 811160003 |

**More clout for strategic research**

* Creavis to operate in new structure from 2014 onward
* Sustainability as an innovation driver

Evonik Industries, one of the world leaders in specialty chemicals, is realigning Creavis, the Group’s strategic innovation unit, on January 1, 2014. This should enable Creavis, which is based in Marl (Germany), to work faster, more flexibly, and more dynamically. Its mission is to investigate topics new to Evonik that possess high business potential but that could also carry high risks. “Our goal is to increase our clout even more,” says Dr. Peter Nagler, Evonik’s Chief Innovation Officer.

The new Portfolio Management unit of Creavis will focus on the identification and assessment of new innovation fields, looking at unconventional ideas for innovation that promise high market potential. The tasks of the newly established growth lines are to generate ideas within the innovation fields under consideration, manage the projects, and transfer these on successful completion to the business units.

The Group is pooling Creavis’ technological expertise in the new Science & Technology unit. Evonik will stay with the tried and tested concept of the project house while allowing greater flexibility in its organization. In the project houses, experts drawn from a number of different operational units research—over a limited period—topics relatively closely connected with Evonik’s existing products and technologies and bring these to application maturity. “The higher flexibility increases the probability of successfully carrying over even more projects into the operational units,” says Professor Stefan Buchholz, Head of Creavis.

In addition, Creavis plans to give more importance to sustainability as a driver of innovation in the future. It is already analyzing the possible impacts of new products and processes on the climate, using a method (carbon footprint estimation methodology, or CFE for short) developed especially for this purpose. This method will now be extended to other environmental and social performance indicators.

In the year 2012 Evonik spent €393 million on research and development, of which about 15 percent went into strategic research. Creavis, the strategic innovation unit of the Group, has around 145 employees, 130 of them in Germany, and is currently working on more than 20 projects. In the last three years alone it has transferred 20 successful projects to the Group’s operational units, thus opening up new businesses for Evonik. These include, for example, SEPURAN® membrane technology for upgrading biogas. Creavis’ researchers also played an important role in setting up Evonik’s biotechnology platform.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.